Germ Cell Tumors - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：51頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Germ Cell Tumors - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Germ Cell Tumors - Pipeline Review, H1 2014’, provides an overview of the Germ Cell Tumors’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Germ Cell Tumors
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Germ Cell Tumors and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Germ Cell Tumors pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Germ Cell Tumors
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Germ Cell Tumors pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Germ Cell Tumors - Pipeline Review, H1 2014’, provides an overview of the Germ Cell Tumors’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Germ Cell Tumors
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Germ Cell Tumors and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Germ Cell Tumors pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Germ Cell Tumors
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Germ Cell Tumors pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Germ Cell Tumors Overview 6
Therapeutics Development 7
Pipeline Products for Germ Cell Tumors - Overview 7
Pipeline Products for Germ Cell Tumors - Comparative Analysis 8
Germ Cell Tumors - Therapeutics under Development by Companies 9
Germ Cell Tumors - Therapeutics under Investigation by Universities/Institutes 10
Germ Cell Tumors - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Germ Cell Tumors - Products under Development by Companies 13
Germ Cell Tumors - Products under Investigation by Universities/Institutes 14
Germ Cell Tumors - Companies Involved in Therapeutics Development 15
ZIOPHARM Oncology, Inc. 15
ArQule, Inc. 16
Philogen S.p.A. 17
Tolero Pharmaceuticals, Inc. 18
Germ Cell Tumors - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
alvocidib hydrocholride - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
palifosfamide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
tivantinib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Allogeneic Tumor Cell Vaccine + [celecoxib] + [cyclophosphamide] - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules to Inhibit Tubulin for Oncology - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
F8IL-4 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Germ Cell Tumors - Recent Pipeline Updates 40
Germ Cell Tumors - Dormant Projects 47
Germ Cell Tumors - Product Development Milestones 48
Featured News & Press Releases 48
Nov 14, 2011: ZIOPHARM Oncology Announces Promising Data From Phase Ib Study Of Palifosfamide In Small Cell Lung And Other Cancers At AACR-NCI-EORTC Meeting 48
May 31, 2008: Amgen Announces Interim Phase 2 Results Of Denosumab In Cell Tumor of Bone 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51
List of Tables
Number of Products under Development for Germ Cell Tumors, H1 2014 7
Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Germ Cell Tumors - Pipeline by ZIOPHARM Oncology, Inc., H1 2014 15
Germ Cell Tumors - Pipeline by ArQule, Inc., H1 2014 16
Germ Cell Tumors - Pipeline by Philogen S.p.A., H1 2014 17
Germ Cell Tumors - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Assessment by Combination Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Germ Cell Tumors Therapeutics - Recent Pipeline Updates, H1 2014 40
Germ Cell Tumors - Dormant Projects, H1 2014 47
List of Figures
Number of Products under Development for Germ Cell Tumors, H1 2014 7
Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Germ Cell Tumors Overview 6
Therapeutics Development 7
Pipeline Products for Germ Cell Tumors - Overview 7
Pipeline Products for Germ Cell Tumors - Comparative Analysis 8
Germ Cell Tumors - Therapeutics under Development by Companies 9
Germ Cell Tumors - Therapeutics under Investigation by Universities/Institutes 10
Germ Cell Tumors - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Germ Cell Tumors - Products under Development by Companies 13
Germ Cell Tumors - Products under Investigation by Universities/Institutes 14
Germ Cell Tumors - Companies Involved in Therapeutics Development 15
ZIOPHARM Oncology, Inc. 15
ArQule, Inc. 16
Philogen S.p.A. 17
Tolero Pharmaceuticals, Inc. 18
Germ Cell Tumors - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
alvocidib hydrocholride - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
palifosfamide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
tivantinib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Allogeneic Tumor Cell Vaccine + [celecoxib] + [cyclophosphamide] - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules to Inhibit Tubulin for Oncology - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
F8IL-4 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Germ Cell Tumors - Recent Pipeline Updates 40
Germ Cell Tumors - Dormant Projects 47
Germ Cell Tumors - Product Development Milestones 48
Featured News & Press Releases 48
Nov 14, 2011: ZIOPHARM Oncology Announces Promising Data From Phase Ib Study Of Palifosfamide In Small Cell Lung And Other Cancers At AACR-NCI-EORTC Meeting 48
May 31, 2008: Amgen Announces Interim Phase 2 Results Of Denosumab In Cell Tumor of Bone 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51
List of Tables
Number of Products under Development for Germ Cell Tumors, H1 2014 7
Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Germ Cell Tumors - Pipeline by ZIOPHARM Oncology, Inc., H1 2014 15
Germ Cell Tumors - Pipeline by ArQule, Inc., H1 2014 16
Germ Cell Tumors - Pipeline by Philogen S.p.A., H1 2014 17
Germ Cell Tumors - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Assessment by Combination Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Germ Cell Tumors Therapeutics - Recent Pipeline Updates, H1 2014 40
Germ Cell Tumors - Dormant Projects, H1 2014 47
List of Figures
Number of Products under Development for Germ Cell Tumors, H1 2014 7
Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28
